Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Inovio Pharmaceuticals
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women aged 18 and above;
Have high grade squamous intraepithelial lesion (HSIL) of the vulva (VIN2 or VIN3) caused by infection with HPV types 16 and/or 18 confirmed at screening visit;
You may not be if
Biopsy-proven differentiated VIN;
Any previous treatment for vulvar HSIL within 4 weeks prior to screening;
Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream;
Pregnant, breastfeeding or considering becoming pregnant within 6 months following the last dose of investigational product;
Immunosuppression as a result of underlying illness or treatment;
Significant acute or chronic medical illness.
Clareo Health | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
